- Home
- Product Information
- 5-HT2B Antagonist
| Compound Code | RQ-00310941 |
|---|---|
| Primary Target Indications | Irritable bowel syndrome |
| Development Stage | Discovery research Portfolio for global development, manufacturing, and marketing rights |
| Product Summary | The major symptoms of irritable bowel syndrome (IBS) are chronic abdominal pain and discomfort (changes in visceral sensitivity) and abnormal bowel movements. Of note is that these are not accompanied by changes in the internal organs. 5-HT2B receptors are widely distributed through-out the human intestinal tract and are thought to be a viable new target for IBS treatment. RaQualia's lead compound, discovered in our discovery research phase, contains selective 5-HT2B receptor antagonist potency, and we are confirming its clear pain-relieving effect in a visceral hypersensitivity model in rats. |
| Non-Confidential Materials |
